Crispr Therapeutics Ag Stock Price Prediction
| CRSP Stock | USD 46.29 0.97 2.05% |
Oversold Vs Overbought
62
Oversold | Overbought |
EPS Estimate Next Quarter (1.33) | EPS Estimate Current Year (5.14) | EPS Estimate Next Year (5.01) | Wall Street Target Price 81.5417 | EPS Estimate Current Quarter (1.42) |
Using Crispr Therapeutics hype-based prediction, you can estimate the value of Crispr Therapeutics AG from the perspective of Crispr Therapeutics response to recently generated media hype and the effects of current headlines on its competitors.
Crispr Therapeutics Hype to Price Pattern
Investor biases related to Crispr Therapeutics' public news can be used to forecast risks associated with an investment in Crispr. The trend in average sentiment can be used to explain how an investor holding Crispr can time the market purely based on public headlines and social activities around Crispr Therapeutics AG. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Some investors profit by finding stocks that are overvalued or undervalued based on market sentiment. The correlation of Crispr Therapeutics' market sentiment to its price can help taders to make decisions based on the overall investors consensus about Crispr Therapeutics.
The fear of missing out, i.e., FOMO, can cause potential investors in Crispr Therapeutics to buy its stock at a price that has no basis in reality. In that case, they are not buying Crispr because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
Crispr Therapeutics after-hype prediction price | USD 47.26 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Crispr |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Crispr Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Crispr Therapeutics After-Hype Price Prediction Density Analysis
As far as predicting the price of Crispr Therapeutics at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Crispr Therapeutics or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Crispr Therapeutics, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Crispr Therapeutics Estimiated After-Hype Price Volatility
In the context of predicting Crispr Therapeutics' stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Crispr Therapeutics' historical news coverage. Crispr Therapeutics' after-hype downside and upside margins for the prediction period are 44.50 and 50.02, respectively. We have considered Crispr Therapeutics' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Crispr Therapeutics is very steady at this time. Analysis and calculation of next after-hype price of Crispr Therapeutics is based on 3 months time horizon.
Crispr Therapeutics Stock Price Prediction Analysis
Have you ever been surprised when a price of a Company such as Crispr Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Crispr Therapeutics backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Crispr Therapeutics, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.04 | 2.77 | 0.02 | 0.02 | 11 Events / Month | 10 Events / Month | In about 11 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | ||
46.29 | 47.26 | 0.00 |
|
Crispr Therapeutics Hype Timeline
Crispr Therapeutics is currently traded for 46.29. The entity has historical hype elasticity of 0.02, and average elasticity to hype of competition of -0.02. Crispr is projected not to react to the next headline, with the price staying at about the same level, and average media hype impact volatility is over 100%. The immediate return on the next news is projected to be very small, whereas the daily expected return is currently at -0.04%. %. The volatility of related hype on Crispr Therapeutics is about 472.35%, with the expected price after the next announcement by competition of 46.27. About 72.0% of the company shares are held by institutions such as insurance companies. The book value of Crispr Therapeutics was currently reported as 22.73. The company recorded a loss per share of 2.79. Crispr Therapeutics had not issued any dividends in recent years. The entity had 333333:100 split on the 19th of July 2016. Given the investment horizon of 90 days the next projected press release will be in about 11 days. Check out Crispr Therapeutics Basic Forecasting Models to cross-verify your projections.Crispr Therapeutics Related Hype Analysis
Having access to credible news sources related to Crispr Therapeutics' direct competition is more important than ever and may enhance your ability to predict Crispr Therapeutics' future price movements. Getting to know how Crispr Therapeutics' peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Crispr Therapeutics may potentially react to the hype associated with one of its peers.
Crispr Therapeutics Additional Predictive Modules
Most predictive techniques to examine Crispr price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Crispr using various technical indicators. When you analyze Crispr charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About Crispr Therapeutics Predictive Indicators
The successful prediction of Crispr Therapeutics stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Crispr Therapeutics AG, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Crispr Therapeutics based on analysis of Crispr Therapeutics hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Crispr Therapeutics's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Crispr Therapeutics's related companies. | 2021 | 2022 | 2023 | 2024 (projected) | Graham Number | 59.45 | 67.37 | 32.2 | 24.66 | Receivables Turnover | 3.0K | 1.86 | 1.67 | 1.59 |
Story Coverage note for Crispr Therapeutics
The number of cover stories for Crispr Therapeutics depends on current market conditions and Crispr Therapeutics' risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Crispr Therapeutics is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Crispr Therapeutics' long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Contributor Headline
Latest Perspective From Macroaxis
Crispr Therapeutics Short Properties
Crispr Therapeutics' future price predictability will typically decrease when Crispr Therapeutics' long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Crispr Therapeutics AG often depends not only on the future outlook of the potential Crispr Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Crispr Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 79.2 M | |
| Cash And Short Term Investments | 1.7 B |
Additional Tools for Crispr Stock Analysis
When running Crispr Therapeutics' price analysis, check to measure Crispr Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Crispr Therapeutics is operating at the current time. Most of Crispr Therapeutics' value examination focuses on studying past and present price action to predict the probability of Crispr Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Crispr Therapeutics' price. Additionally, you may evaluate how the addition of Crispr Therapeutics to your portfolios can decrease your overall portfolio volatility.